Valuation: Candel Therapeutics, Inc.

Market Cap 726M 648M 596M 541M 1.03B 68.07B 1.05B 7.13B 2.84B 36.44B 2.73B 2.67B 115B P/E 2026 *
-6.72x
P/E 2027 * -8.16x
Enterprise Value 726M 648M 596M 541M 1.03B 68.07B 1.05B 7.13B 2.84B 36.44B 2.73B 2.67B 115B EV / Sales 2026 *
-
EV / Sales 2027 * 17.3x
Free-Float
85.21%
Yield 2026 *
-
Yield 2027 * -
11-06 Candel Therapeutics Presents Clinical and Biomarker Data for Aglatimagene Besadenovec and Linoserpaturev Across Clinical-Stage Portfolio CI
10-22 Candel Therapeutics, Inc. Appoints Maria Ostrovsky as General Counsel, Effective November 3, 2026 CI
10-01 Candel Therapeutics, Inc. Announces Publication Of Final Phase 2a Clinical Trial Results Of Aglatimagene Besadenovec Plus Valacyclovir In Patients With Stage III/IV NSCLC CI
09-30 Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Show Durable Local and Systemic Immune Activation After Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer CI
09-30 Candel Therapeutics, Inc. Presents New Biomarker Data From Phase 3 Clinical Trial Of Aglatimagene Besadenovec In Localized Prostate Cancer At ASTRO 2026 CI
09-21 Candel Therapeutics Shares Rise After BofA Upgrade MT
09-21 BofA Upgrades Candel Therapeutics to Buy From Neutral, Price Target is $18 MT
09-14 Candel Therapeutics Insider Sold Shares Worth $3,160,783, According to a Recent SEC Filing MT
09-10 Candel Therapeutics, Inc. Announces Appointment of Martine Zimmermann to Board of Directors, Effective September 8, 2026 CI
08-14 BofA Adjusts Price Target on Candel Therapeutics to $12 From $9 MT
08-13 Candel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-13 Candel Therapeutics Q2 Loss Widens MT
08-13 Earnings Flash (CADL) Candel Therapeutics Posts Q2 Net Loss $0.52 a Share, vs. FactSet Est of $0.21 Loss MT

Last Transcript: Candel Therapeutics, Inc.

1 day+8.46%
1 week+16.87%
Current month+13.93%
1 month-4.53%
3 months-10.39%
6 months+13.65%
Current year+67.96%
1 week 7.92
Extreme 7.92
9.84
1 month 7.7
Extreme 7.7
10.18
Current year 4.44
Extreme 4.44
14
1 year 4.35
Extreme 4.35
14
3 years 0.77
Extreme 0.77
14.6
5 years 0.66
Extreme 0.66
14.6
10 years 0.66
Extreme 0.66
14.78
Manager TitleAgeSince
Chief Executive Officer 66 01/09/2020
Director of Finance/CFO 41 12/01/2024
Chief Tech/Sci/R&D Officer 57 12/09/2022
Director TitleAgeSince
Director/Board Member 80 01/09/2017
Director/Board Member 66 01/09/2020
Chairman 70 15/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Free

Director

380 0.0005%
30/09/26 Free

Chairman

2,189 0.0029%
30/09/26 Free

Director

1,325 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
+8.46%+16.87%+88.29%+990.80% 726M
+2.24%+8.40%+58.47%+69.00% 68.22B
+4.66%+8.90%+16.93%+85.41% 59.82B
-0.60%+1.73%+24.32%+94.40% 56.07B
+2.55%+15.52%+30.43%+120.17% 47.67B
+2.58%+7.89%+32.49%+45.30% 45.95B
+4.09%+6.37%+228.06%+899.75% 43.29B
-0.47%+9.38%+27.53%+52.40% 35.66B
+3.80%-1.00%+98.16%+66.79% 34.73B
+1.48%+6.21%-38.80%+395.73% 25.47B
Average +2.88%+8.42%+56.59%+281.97% 42B
Weighted average by Cap. +2.33%+7.85%+54.23%+184.04%

Financials

2026 *2027 *
Net sales - 41.92M 37.41M 34.43M 31.25M 59.22M 3.93B 60.69M 412M 164M 2.1B 157M 154M 6.62B
Net income -102M -90.65M -83.41M -75.7M -143M -9.52B -147M -998M -398M -5.1B -381M -373M -16.05B -92.33M -82.41M -75.83M -68.83M -130M -8.65B -134M -907M -362M -4.63B -347M -339M -14.59B
Net Debt - -
Projected Income Statement - Annual - Candel Therapeutics, Inc.
Logo Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Employees
55
Date Price Change Volume
09/11/26 $9.490 +8.46% 1,371,305
06/11/26 $8.750 +8.83% 955,020
05/11/26 $8.040 -11.16% 1,228,485
04/11/26 $9.050 +2.61% 993,819
03/11/26 $8.820 +8.62% 3,304,421
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Candel Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
9.490USD
Average target price
22.11USD
Spread / Average Target
+132.99%
  1. Stock Market
  2. Stocks
  3. CADL Stock